Tech startups such as Prefix, Lightcast, Senhwa Biosciences, among others, have announced their venture capital funding to bolster innovation and business growth.
Prefix Raises $7.5 mn
Prefix announced it has raised $7.5 million in a seed funding round co-led by Collide Capital and Slow Ventures, with participation from Connexa Capital, Elevated Inc., I2BF, and Bienville Capital. The company develops a facility management platform designed for multi-site restaurant and retail operators. The funding will be used to enhance product development, scale AI-driven infrastructure, and expand go-to-market activities including sales and marketing. Prefix’s platform focuses on improving operational efficiency across distributed locations by centralizing maintenance workflows and service coordination. The investment supports the company’s efforts to scale its technology and increase adoption among enterprise customers managing complex facility operations across multiple sites.
Lightcast Raises $27 mn
Lightcast announced it has raised $27 million in funding from existing investors to accelerate commercialization of its Envisia platform. The company focuses on workforce intelligence and labor market analytics, providing data-driven insights to enterprises, governments, and educational institutions. The funding will support further development of its technology platform, expansion of commercial operations, and scaling of its data capabilities. Lightcast’s solutions enable organizations to analyze workforce trends, skills demand, and economic data to support strategic decision-making. The financing reflects continued investment in data analytics platforms that support workforce planning and economic intelligence, particularly as organizations increasingly rely on data-driven insights for talent management and policy development.
Senhwa Biosciences Secures Up to NT$500 mn
Senhwa Biosciences announced a strategic funding agreement with GEM Yield Bahamas Limited, under which GEM will provide up to NT$500 million. The funding is intended to support Senhwa’s clinical pipeline, AI-driven drug discovery initiatives, and global expansion strategy. The agreement was formalized through a memorandum of understanding between the two organizations. Senhwa focuses on developing therapeutics and integrating artificial intelligence into drug discovery processes. The capital will be used to accelerate development programs and enhance research capabilities. The funding arrangement reflects continued investment in biotechnology companies leveraging AI technologies to improve efficiency in drug development and expand clinical research activities globally.
THASNIYA VP
